会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 4. 发明申请
    • DRUG CONJUGATES
    • 药物联合
    • US20080139815A1
    • 2008-06-12
    • US11856317
    • 2007-09-17
    • Iwao Ojima
    • Iwao Ojima
    • C07D213/70C07C323/62C07D305/14
    • C07D305/14A61K47/6803A61K47/6889C07C323/62C07D213/71
    • A compound having the formula Y-A-Z, wherein:A is a 5, 6, or 7 member ring that is monocyclic or is fused to 1 to 3 additional 4 to 8 member rings; wherein ring A and, independently, the fused additional rings are carbocyclic or heterocyclic, and saturated or unsaturated, wherein unsaturated rings are aromatic or non-aromatic; wherein Y and Z are substituents at adjacent positions on ring A;Y represents: Z represents: X and E represent O, S, or NRa or NRb; each of a, b, c, d, e and f independently represents 0 or 1; a+c equals 0, 1, or 2; b+d equals 0, 1, or 2; a+b+c+d+e+f equals 1, 2, or 3; provided that when f is 1, then d is 1, and when d is 0, then f is 0; and when both e and b are 0, then neither R1 nor R2 is chloro or bromo; v represents 0 or 1, provided that when v is 0, then J is hydrogen, a metal ion, or a quaternary ammonium ion, and X is O and G is H;either G is hydrogen, a metal ion, a quaternary ammonium ion, lower alkyl, or comprised of a pharmaceutically active chemical compound or the precursor thereof; or X-G represents a carbonyl-activating group;J is lower alkyl, aryl, heteroaryl, omega-hydroxycarbonyl-(lower alkyl), omega-(lower alkoxy)carbonyl-(lower alkyl), omega-(X-G)-carbonyl-(lower alkyl) group, or comprised of a specific binding agent; and Ra, Rb, R1, R2, R3, R4 are as defined in the specification.
    • 具有式Y-A-Z的化合物,其中:A为5,6或7元环,其为单环或稠合至1至3个另外的4至8个成员环; 其中环A和独立地稠合的另外的环是碳环或杂环的,饱和或不饱和的,其中不饱和环是芳族或非芳族的; 其中Y和Z是环A上相邻位置的取代基; Y表示:Z表示:X和E表示O,S或NR a或NR b。 a,b,c,d,e和f各自独立地表示0或1; a + c等于0,1或2; b + d等于0,1或2; a + b + c + d + e + f等于1,2或3; 条件是当f为1时,d为1,当d为0时,f为0; 当e和b都为0时,R 1和R 2都不是氯或溴; v表示0或1,条件是当v为0时,J为氢,金属离子或季铵离子,X为O且G为H; G是氢,金属离子,季铵离子,低级烷基,或由药物活性化合物或其前体组成; 或X-G表示羰基活化基团; J是低级烷基,芳基,杂芳基,ω-羟基羰基 - (低级烷基),ω-(低级烷氧基)羰基 - (低级烷基),ω-(XG) - 羰基 - (低级烷基) 粘合剂; R 1,R 2,R 1,R 2,R 3,R 3, R 4如本说明书中所定义。
    • 6. 发明授权
    • Taxoid anti-tumor agents and pharmaceutical compositions thereof
    • 紫杉烷类抗肿瘤剂及其药物组合物
    • US6100411A
    • 2000-08-08
    • US608003
    • 1996-03-04
    • Iwao Ojima
    • Iwao Ojima
    • A61K31/335A61K31/337A61P35/00C07D305/14C07F7/18
    • C07D305/14C07F7/1856Y02P20/55
    • This invention relates to a taxoid of the formula (I): ##STR1## wherein R.sup.1 is a C.sub.3 -C.sub.5 alkyl or alkenyl or trifluoromethyl radical;R.sup.2 is a C.sub.3 -C.sub.5 branched alkyl radical;R.sup.3 and R.sup.4 are independently selected from hydrogen and hydroxyl protecting groups including functional groups which increase the water solubility of the taxoid antitumor agent;R.sup.5 is a hydrogen, an acyl radical, or an alkoxylcarbonyl or carbamoyl radical; andR.sup.6 is an acyl radical.The compounds of formula I are useful as antitumor agents or their precursors. This invention also relates to a pharmaceutical composition having antineoplastic activity comprising the compound of formula (I) and a physiologically acceptable carrier and method of treatment using the compound of formula I.
    • 本发明涉及式(I)的紫杉烷:其中R1是C3-C5烷基或烯基或三氟甲基; R2是C3-C5支链烷基; R3和R4独立地选自氢和羟基保护基,包括增加紫杉烷类抗肿瘤剂的水溶性的官能团; R5是氢,酰基或烷氧基羰基或氨基甲酰基; R6为酰基。 式I的化合物可用作抗肿瘤剂或其前体。 本发明还涉及具有抗肿瘤活性的药物组合物,其包含式(I)化合物和生理学上可接受的载体和使用式I化合物的治疗方法。